Mar182024UncategorizedCategory: UncategorizedBy Charlotte Maddalena18 March 2024 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastomaNextNext post:Six new projects supported by our FoundationRelated PostsOrphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024Six new projects supported by our Foundation18 March 2024ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024Seven new projects supported by our Foundation8 January 2024Newsletter December 202318 December 2023Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023
Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin18 April 2024
ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma9 January 2024
Orphelia Pharma secures US patent covering KIZFIZO®, first drinkable formulation of temozolomide29 November 2023